Photo taken from Mohammed Shahait/X
Jan 19, 2024, 19:10
Mohammed Shahait: Our new study “Termination of Urologic Cancer Trials”
Mohammed Shahait, Clinical Instructor of Urology at The University of Pennsylvania and The University of Pittsburgh Medical Center, shared on X/Twitter:
“Our new study “Termination of Urologic Cancer Trials” at JCO Global Oncology.
25% termination rate.
Main cause: Low patient accrual.
Risk factors: University funding, single-center, small sample.”
Additional information.
Source: Mohammed Shahait/X